• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Achieve Life Sciences Announces Partnership with Omnicom to Execute Integrated, Data-Driven Launch of the First Potential New Treatment for Nicotine Dependence in Nearly Two Decades

    6/26/25 4:02:00 PM ET
    $ACHV
    $OMC
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care
    Advertising
    Consumer Discretionary
    Get the next $ACHV alert in real time by email

    Omnicom cross-agency collaboration to drive technology-led, innovative launch strategy

    Partnership brings together promising science, top-tier talent, and advanced technologies to enable a faster, smarter, and more effective path to address a critical public health need

    SEATTLE and VANCOUVER, British Columbia, June 26, 2025 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (NASDAQ:ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment of nicotine dependence for smoking cessation, today announced it has named Omnicom (NYSE:OMC) as its strategic innovation partner and agency of record to lead initiatives in support of Achieve's planning for U.S. commercial launch.

    "We're excited to expand our partnership with Omnicom, building on the strong foundation we've established over the past several years," said Jaime Xinos, Chief Commercial Officer of Achieve Life Sciences. "This fully integrated extension of our commercial team shares the belief that the first treatment innovation for nicotine dependence in decades should be matched by an equally modern and strategic launch approach."

    Led by Omnicom's technology powerhouse, Credera, Achieve's U.S. launch platform is being developed based on world-class, AI-enabled marketing technology proven across healthcare and other industries to enhance precision targeting, optimize channel performance, and accelerate meaningful engagement with both healthcare professionals and patients.

    "To be selected by Achieve to help address a major public health crisis is truly an honor," said Michael Collins, President, Health & Wellness for Omnicom Advertising Collective. "Over the past several years, Achieve Life Sciences has been singularly focused on preparing to transform the nicotine dependence market and we are deeply committed to building a best-in-class approach with top talent and tools from across the network to help Achieve realize the full potential of cytisinicline."

    Along with Credera, to deliver a comprehensive and connected commercialization strategy, Omnicom has assembled a unified agency team drawing on specialized talent from Goodby, Silverstein & Partners, DDB Health, and Ketchum Health. This cross-functional team will provide expertise in consumer brand development, medical education, and strategic public relations and communications, applying proven insights from across industries to support a launch strategy designed to set a new standard for biopharma commercialization.

    Xinos continued, "As an emerging biopharma company, we recognize we can't follow the traditional playbook historically used to launch new medicines. We're designing a launch platform that's purpose-built for a company bringing its first product to market in today's environment. It leverages data-driven insights to guide decisions and deploy resources with precision, agility, and efficiency. These aren't untested ideas—they're established best practices in marketing excellence, and we're applying them with focus and intent to drive value across our stakeholders."

    Smoking remains the leading cause of preventable death and disease in the U.S., with over 29 million adults still smoking. Achieve has successfully completed two Phase 3 studies with cytisinicline for smoking cessation and has fully enrolled its ongoing open-label safety study. Achieve announced it submitted its new drug application (NDA) for cytisinicline as a treatment of nicotine dependence for smoking cessation on June 25, 2025. If approved, Achieve aims to help address this ongoing public health crisis by making cytisinicline available to those ready to quit and providing them with a new, evidence-based path to cessation.

    Achieve's collaboration with Omnicom enables the integration of innovative technologies like generative AI, predictive analytics and social listening to enhance targeting and personalization and will also include partnerships with healthcare apps, pharmacies, and data providers to expand the reach and depth of insights, making Achieve's approach uniquely comprehensive.

    "We're so proud to have been chosen by Achieve Life Sciences and to be part of history by addressing one of the biggest public health issues of our time and applying our latest technologies and offerings to ensure a highly successful launch," said Michele Markus, Head of Global Health Accounts for Omnicom. "This issue is personal for many of us and the commitment and dedication of our integrated team reflects our belief in their mission – one we know has the ability to significantly save and change lives."

    About Achieve

    Achieve Life Sciences is a late-stage specialty pharmaceutical company committed to addressing the global smoking health and nicotine dependence epidemic through the development and commercialization of cytisinicline. In June 2025, the company submitted its New Drug Application to the FDA for cytisinicline as a treatment of nicotine dependence for smoking cessation in adults, based on two successfully completed Phase 3 studies and its fully enrolled open-label safety study. Additionally, the company has completed a Phase 2 study with cytisinicline in vaping cessation and conducted a successful end-of-Phase 2 meeting with the FDA for a future vaping indication.

    About Cytisinicline

    There are approximately 29 million adults in the United States who smoke combustible cigarettes.1 Tobacco use is currently the leading cause of preventable death that is responsible for more than eight million deaths worldwide and nearly half a million deaths in the United States annually.2,3 More than 87% of lung cancer deaths, 61% of all pulmonary disease deaths, and 32% of all deaths from coronary heart disease are attributable to smoking and exposure to secondhand smoke.3

    In addition, there are approximately 17 million adults in the United States who use e-cigarettes, also known as vaping.4 In 2024, approximately 1.6 million middle and high school students in the United States reported using e-cigarettes.5 There are no FDA-approved treatments indicated specifically as an aid to nicotine e-cigarette cessation. Cytisinicline has been granted Breakthrough Therapy designation by the FDA to address this critical need.

    Cytisinicline is a plant-based alkaloid with a high binding affinity to the nicotinic acetylcholine receptor. It is believed to aid in treating nicotine addiction for smoking and e-cigarette cessation by interacting with nicotine receptors in the brain, reducing the severity of nicotine craving symptoms, and reducing the reward and satisfaction associated with nicotine products. Cytisinicline is an investigational product candidate being developed as a treatment of nicotine dependence for smoking cessation and has not been approved by the Food and Drug Administration for any indication in the United States.

    About Omnicom Group Inc. 

    Omnicom Group Inc. (NYSE:OMC) (www.omnicomgroup.com) is a leading global marketing and corporate communications company. Omnicom's branded networks and numerous specialty firms provide advertising, strategic media planning and buying, digital and interactive marketing, direct and promotional marketing, public relations and other specialty communications services to over 5,000 clients in more than 70 countries. Follow us on X for the latest news. 

    About Goodby, Silverstein & Partners

    At Goodby Silverstein & Partners, we believe in mass intimacy—creating campaigns that speak to millions but feel like they're made just for you. We combine brilliant strategy, breakthrough creativity and the innovative use of technology to build enduring ideas that drive results for some of the world's most iconic brands. While maintaining our independent spirit, our network affiliation provides global scale and access to proprietary tools and discipline-specific specialists including PR, multicultural, experiential and media. Visit us at goodbysilverstein.com.

    About DDB Health

    DDB Health is a global network of healthcare communications companies. At DDB Health we are 100% dedicated to healthcare, particularly in the specialty science space. DDB Health specializes in HCP promotions, including brand and campaign development, insight/data generation, portfolio management, scientific branding, and market-shaping activities, ensuring customers are educated in the latest advancements to help them engage effectively with patients and caregivers. We are uniquely supported by a range of specialized services, including multichannel engagement, innovation experts, strategic planning, medical execution, and data and analytics. As a part of Omnicom Health, DDB Health has access to in-network resources with expertise in payer, media, and medical education. Visit us at ddbhealth.com.

    About Credera

    Credera is a global, boutique consulting firm that creates measurable results at the intersection of strategy, data, innovation, and technology. Credera works with leading companies across the globe from strategy through execution at offices in 16 countries. Credera's deep business acumen and technical expertise, combined with a true dedication to building trusted relationships, unlocks remarkable performance for our clients. Our mission is to make an extraordinary impact on our clients, our people, and our communities. Visit us at Credera.

    About Ketchum

    Established in 1923, Ketchum's century of continuous evolution is a testament to our progress. Our storied journey is fueled by our guiding principles of empathy and intelligence. Progress allows us to create a thriving environment where we embrace innovation and deliver excellence with our people and partners, producing work that matters. Driven by data, we develop culture-first work at the intersection of industry and capability. With 150+ Cannes Lions, our global communications consultancy is one of the most creatively awarded firms in our industry. We are Ketchum: Progress at Work. For more information on Ketchum, a part of Omnicom PR Group, visit www.ketchum.com.

    Forward Looking Statements

    This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding the timing and nature of cytisinicline clinical development and regulatory review and approval, data results and commercialization activities, the potential market size for cytisinicline, the potential benefits, efficacy, safety and tolerability of cytisinicline, the development and effectiveness of new treatments, and the successful commercialization of cytisinicline. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. Achieve may not actually achieve its plans or product development goals in a timely manner, if at all, or otherwise carry out its intentions or meet its expectations or projections disclosed in these forward-looking statements. These statements are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those described in the forward-looking statements, including, among others, the risk that cytisinicline may not demonstrate the hypothesized or expected benefits; the risk that Achieve may not be able to obtain additional financing to fund the development and commercialization of cytisinicline; the risk that cytisinicline will not receive regulatory approval in a timely manner or at all, or be successfully commercialized; the risk that new developments in the smoking and vaping cessation landscapes require changes in business strategy or clinical development plans; the risk that Achieve's intellectual property may not be adequately protected; general business and economic conditions; risks related to the impact on our business of macroeconomic and geopolitical conditions, including fluctuating inflation, interest and tariff rates, volatility in the debt and equity markets, actual or perceived instability in the global banking system, global health crises and pandemics and geopolitical conflict and the other factors described in the risk factors set forth in Achieve's filings with the Securities and Exchange Commission from time to time, including Achieve's Annual Reports on Form 10-K and Quarterly Reports on Form 10-Q. Achieve undertakes no obligation to update the forward-looking statements contained herein or to reflect events or circumstances occurring after the date hereof, other than as may be required by applicable.

    Achieve Contact

    Nicole Jones

    [email protected]

    425-686-1510

    References

    1VanFrank B, Malarcher A, Cornelius ME, Schecter A, Jamal A, Tynan M. Adult Smoking Cessation — United States, 2022. MMWR Morb Mortal Wkly Rep 2024;73:633–641.

    2World Health Organization. WHO Report on the Global Tobacco Epidemic, 2019. Geneva: World Health Organization, 2017.

    3U.S. Department of Health and Human Services. The Health Consequences of Smoking – 50 Years of Progress. A Report of the Surgeon General, 2014.

    4Vahratian A, Briones EM, Jamal A, Marynak KL. Electronic cigarette use among adults in the United States, 2019–2023. NCHS Data Brief, no 524. Hyattsville, MD: National Center for Health Statistics. 2025. DOI: https://dx.doi.org/ 10.15620/cdc/174583.

    5Jamal A, Park-Lee E, Birdsey J, et al. Tobacco Product Use Among Middle and High School Students — National Youth Tobacco Survey, United States, 2024. MMWR Morb Mortal Wkly Rep 2024;73:917–924.



    Primary Logo

    Get the next $ACHV alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $ACHV
    $OMC

    CompanyDatePrice TargetRatingAnalyst
    Omnicom Group Inc.
    $OMC
    6/25/2025$80.00Overweight → Equal Weight
    Barclays
    Omnicom Group Inc.
    $OMC
    6/23/2025$80.00Underperform → Neutral
    BofA Securities
    Omnicom Group Inc.
    $OMC
    2/14/2025Buy → Hold
    Argus
    Achieve Life Sciences Inc.
    $ACHV
    11/14/2024$12.00Buy
    Rodman & Renshaw
    Omnicom Group Inc.
    $OMC
    10/16/2024$118.00 → $119.00Overweight
    JP Morgan
    Omnicom Group Inc.
    $OMC
    10/16/2024$106.00 → $110.00Overweight → Equal Weight
    Wells Fargo
    Achieve Life Sciences Inc.
    $ACHV
    9/27/2024$20.00Strong Buy
    Raymond James
    Omnicom Group Inc.
    $OMC
    5/7/2024$100.00 → $110.00Equal Weight → Overweight
    Barclays
    More analyst ratings

    $ACHV
    $OMC
    SEC Filings

    See more
    • SEC Form 11-K filed by Omnicom Group Inc.

      11-K - OMNICOM GROUP INC. (0000029989) (Filer)

      6/30/25 4:01:36 PM ET
      $OMC
      Advertising
      Consumer Discretionary
    • Achieve Life Sciences Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits

      8-K - ACHIEVE LIFE SCIENCES, INC. (0000949858) (Filer)

      6/27/25 5:28:32 PM ET
      $ACHV
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • SEC Form 424B5 filed by Achieve Life Sciences Inc.

      424B5 - ACHIEVE LIFE SCIENCES, INC. (0000949858) (Filer)

      6/27/25 4:59:29 PM ET
      $ACHV
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $ACHV
    $OMC
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Achieve Life Sciences Announces Closing of Public Offering of Common Stock and Partial Exercise of Underwriters' Option to Purchase Additional Securities

      SEATTLE and VANCOUVER, British Columbia, June 30, 2025 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (NASDAQ:ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment of nicotine dependence for smoking cessation, today announced the closing of its underwritten public offering of 15,000,000 shares of its common stock and accompanying common warrants to purchase up to 16,766,666 shares of common stock at a public offering price of $3.00 per share and accompanying warrant, which includes common warrants to purchase up to 1,766,666 shares issued upon the partial exercise by the underwriters of their option to

      6/30/25 7:52:40 PM ET
      $ACHV
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Achieve Life Sciences Announces Pricing of $45.0 Million Underwritten Public Offering

      SEATTLE and VANCOUVER, British Columbia, June 26, 2025 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (NASDAQ:ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment of nicotine dependence for smoking cessation, today announced the pricing of an underwritten public offering of 15,000,000 shares of its common stock and accompanying common warrants to purchase up to 15,000,000 shares of common stock. The shares of common stock and accompanying common warrants were offered collectively at a price to the public of $3.00 per share and accompanying common warrant. Achieve has also granted the underwriters a 30-

      6/26/25 11:43:33 PM ET
      $ACHV
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Achieve Life Sciences Announces Proposed Underwritten Public Offering

      SEATTLE and VANCOUVER, British Columbia, June 26, 2025 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (NASDAQ:ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment of nicotine dependence for smoking cessation, today announced a proposed underwritten public offering in which it intends to offer and sell shares of its common stock (or pre-funded warrants to purchase common stock in lieu thereof) and accompanying common warrants to purchase common stock (or pre-funded warrants to purchase common stock in lieu thereof). In addition, Achieve intends to grant the underwriters a 30-day option to purchase up to

      6/26/25 4:03:00 PM ET
      $ACHV
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $ACHV
    $OMC
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Financial Officer Oki Mark K bought $28,887 worth of shares (10,000 units at $2.89) (SEC Form 4)

      4 - ACHIEVE LIFE SCIENCES, INC. (0000949858) (Issuer)

      3/19/25 4:38:43 PM ET
      $ACHV
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Chieve Executive Officer Stewart Richard Alistair bought $28,598 worth of shares (10,000 units at $2.86), increasing direct ownership by 20% to 60,876 units (SEC Form 4)

      4 - ACHIEVE LIFE SCIENCES, INC. (0000949858) (Issuer)

      3/19/25 4:32:22 PM ET
      $ACHV
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Stewart Richard Alistair bought $45,850 worth of shares (10,000 units at $4.58), increasing direct ownership by 35% to 38,501 units (SEC Form 4)

      4 - ACHIEVE LIFE SCIENCES, INC. (0000949858) (Issuer)

      3/6/24 4:49:23 PM ET
      $ACHV
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $ACHV
    $OMC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Omnicom downgraded by Barclays with a new price target

      Barclays downgraded Omnicom from Overweight to Equal Weight and set a new price target of $80.00

      6/25/25 7:52:17 AM ET
      $OMC
      Advertising
      Consumer Discretionary
    • Omnicom upgraded by BofA Securities with a new price target

      BofA Securities upgraded Omnicom from Underperform to Neutral and set a new price target of $80.00

      6/23/25 8:01:50 AM ET
      $OMC
      Advertising
      Consumer Discretionary
    • Omnicom downgraded by Argus

      Argus downgraded Omnicom from Buy to Hold

      2/14/25 8:36:38 AM ET
      $OMC
      Advertising
      Consumer Discretionary

    $ACHV
    $OMC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Senior VP, Gen. Counsel & Sec. Januzzi Louis F was granted 6,770 shares, increasing direct ownership by 23% to 35,728 units (SEC Form 4)

      4 - OMNICOM GROUP INC. (0000029989) (Issuer)

      7/3/25 4:50:22 PM ET
      $OMC
      Advertising
      Consumer Discretionary
    • Director Gerstein Mark D was granted 1,025 shares, increasing direct ownership by 9% to 12,020 units (SEC Form 4)

      4 - OMNICOM GROUP INC. (0000029989) (Issuer)

      7/3/25 4:33:04 PM ET
      $OMC
      Advertising
      Consumer Discretionary
    • Director Coleman Leonard S Jr was granted 712 shares, increasing direct ownership by 2% to 46,463 units (SEC Form 4)

      4 - OMNICOM GROUP INC. (0000029989) (Issuer)

      7/3/25 4:32:48 PM ET
      $OMC
      Advertising
      Consumer Discretionary

    $ACHV
    $OMC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Achieve Life Sciences Inc.

      SC 13G/A - ACHIEVE LIFE SCIENCES, INC. (0000949858) (Subject)

      11/12/24 12:14:09 PM ET
      $ACHV
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • SEC Form SC 13G filed by Omnicom Group Inc.

      SC 13G - OMNICOM GROUP INC. (0000029989) (Subject)

      11/8/24 10:46:38 AM ET
      $OMC
      Advertising
      Consumer Discretionary
    • SEC Form SC 13G filed by Achieve Life Sciences Inc.

      SC 13G - ACHIEVE LIFE SCIENCES, INC. (0000949858) (Subject)

      11/4/24 10:59:37 AM ET
      $ACHV
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $ACHV
    $OMC
    Leadership Updates

    Live Leadership Updates

    See more
    • Adrienne Connell Appointed Managing Director of FleishmanHillard Canada

      Experienced Agency Leader to Guide Agency's Growth and Integration in Canada ST. LOUIS, June 24, 2025 /PRNewswire/ -- FleishmanHillard today announced the appointment of Adrienne Connell as managing director of its Canada operations. Connell will oversee strategic direction, growth and client service across the agency's Canadian markets as the firm continues to evolve its presence in the region. She will report to Della Sweetman, president, Americas and chief strategy officer. The appointment coincides with the agency's rebrand from FleishmanHillard Highroad in the region to F

      6/24/25 8:45:00 AM ET
      $OMC
      Advertising
      Consumer Discretionary
    • Susan Catalano Joins Omnicom as Chief People Officer for the U.S.

      NEW YORK, May 7, 2025 /PRNewswire/ -- Omnicom (NYSE:OMC) today announced the appointment of Susan Catalano as Chief People Officer. In this newly created position, Catalano is responsible for leading the company's human resource (HR) organization and operations in the U.S., overseeing a dedicated team of HR professionals. She reports directly to Omnicom's Chairman and CEO John Wren. Catalano is a strategic HR leader bringing extensive global experience and a track record for managerial and operational excellence and strong decision making. She is an expert in driving large-scale transformational change through organizational re-design, talent management, and operations. She has successfully

      5/7/25 12:39:00 PM ET
      $OMC
      Advertising
      Consumer Discretionary
    • Achieve Life Sciences Appoints Dr. Kristen Slaoui and Nancy Phelan to its Board of Directors

      SEATTLE and VANCOUVER, British Columbia, Jan. 10, 2025 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (NASDAQ:ACHV), a late-stage pharmaceutical company focused on the global development and commercialization of cytisinicline for smoking cessation and nicotine dependence, today announced that Kristen Slaoui, Ph.D., and Nancy Phelan will join its Board of Directors. Achieve also announced that current Board member, Vaughn Himes, Ph.D., has retired and resigned from the Board. He will continue to provide consulting services to the company. "We are delighted to welcome Kristen and Nancy to our Board of Directors," said Tom King, Executive Chairman of Achieve's Board of Directors. "Their wea

      1/10/25 8:30:00 AM ET
      $ACHV
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $ACHV
    $OMC
    Financials

    Live finance-specific insights

    See more
    • Achieve Life Sciences Reports First Quarter 2025 Financial Results and Highlights Updates in Cytisinicline Program

      Reiterates Planned Submission of an NDA for Cytisinicline to FDA in June 2025 Company to Host Conference Call at 8:30 AM EDT Today, Tuesday, May 13, 2025 SEATTLE and VANCOUVER, British Columbia, May 13, 2025 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (NASDAQ:ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment of nicotine dependence for smoking cessation, today announced its financial results for first quarter 2025 and confirmed that it plans to submit the upcoming New Drug Application (NDA) for cytisinicline to the U.S. Food and Drug Administration (FDA) in June 2025. "The Achieve team is fully

      5/13/25 7:30:00 AM ET
      $ACHV
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Omnicom Declares Dividend

      NEW YORK, May 6, 2025 /PRNewswire/ -- The Board of Directors of Omnicom (NYSE: OMC) declared a quarterly dividend of 70 cents per outstanding share of the corporation's common stock. The dividend is payable on July 9, 2025 to Omnicom common shareholders of record at the close of business on June 10, 2025. About OmnicomOmnicom (NYSE: OMC) is a leading provider of data-inspired, creative marketing and sales solutions. Omnicom's iconic agency brands are home to the industry's most innovative communications specialists who are focused on driving intelligent business outcomes for their clients. The company offers a wide range of services in advertising, strategic media planning and buying, preci

      5/6/25 4:31:00 PM ET
      $OMC
      Advertising
      Consumer Discretionary
    • Achieve Life Sciences to Announce First Quarter 2025 Financial Results and Host Conference Call and Webcast on May 13, 2025

      SEATTLE and VANCOUVER, British Columbia, May 06, 2025 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (NASDAQ:ACHV) a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment of nicotine dependence for smoking cessation, today announced that it will report its first quarter 2025 financial results and provide a corporate update on the cytisinicline development program on Tuesday May 13, 2025, at 8:30 AM EDT. To access the webcast, please use the following link: 1Q25 Earnings Webcast. Alternatively, you may access the live conference call by dialing 877-269-7756 (U.S. & Canada) or 201-689-7817 (International) and r

      5/6/25 8:30:00 AM ET
      $ACHV
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care